Common asthma drug cuts COVID-19 hospitalization risk, recovery time - Oxford study (reuters.com)
(Reuters) - A commonly used asthma treatment appears to reduce the need for hospitalizations as well as recovery time for COVID-19 patients if given within seven days of symptoms appearing, researchers at the University of Oxford said on Tuesday.
The findings were made following a mid-stage study of the steroid budesonide, sold as Pulmicort by AstraZeneca Plc and also used for treating smoker’s lung.
- Log in to post comments
Source